Sign in

You're signed outSign in or to get full access.

Kevin Peterson

Senior Equity Analyst at Petersen Capital

Kevin Peterson is a Senior Equity Analyst at Petersen Capital, specializing in technology and financial services sectors with coverage focused on companies such as Apple, Microsoft, JPMorgan Chase, and Visa. Known for his data-driven approach, Peterson ranks in the top 15% of Wall Street analysts with a documented success rate of 72% and an average annualized return exceeding 18% on his stock recommendations, according to third-party tracking platforms. He began his career at Merrill Lynch in 2013 as an analyst, moved to Barclays in 2015, and joined Petersen Capital in 2019, where he has distinguished himself with in-depth equity research and actionable investment calls. Peterson holds FINRA Series 7 and 63 licenses and has been recognized for his rigorous coverage and accuracy in earnings estimate revisions.

Kevin Peterson's questions to BIOSTEM TECHNOLOGIES (BSEM) leadership

Question · Q2 2024

Kevin Peterson of Petersen Capital asked for an overview of the key drivers behind the rapid growth of AmnioWrap2 and the company's outlook for this trend.

Answer

Executive Jason Matuszewski attributed the growth to a successful partnership with Venture Medical, which has effectively communicated the value of the BioRetain technology. He highlighted the product's clinical success, validated by a published retrospective study, and a strategic focus on the mobile wound care setting, particularly on the West Coast, which has improved patient access and outcomes.

Ask follow-up questions

Fintool

Fintool can predict BIOSTEM TECHNOLOGIES logo BSEM's earnings beat/miss a week before the call